United States-based Charles River has signed a multi-year drug discovery collaboration with Japan-based Takeda Pharmaceutical Company, it was reported yesterday.
Both firms will launch multiple integrated programs across Takeda's four core therapeutic areas, oncology, gastroenterology, neuroscience, and rare disease, with the ultimate goal of delivering preclinical candidates that Takeda can advance into clinical development. The companies say that the collaboration integrates Charles River's extensive integrated drug discovery expertise and deep scientific bench with Takeda's investments in human data and translation.
According to the terms of the contract, Takeda will pay Charles River a one-time, upfront fee to establish the collaboration. Charles River will be eligible to receive development payments with a potential value of more than USD50m per program in preclinical and clinical milestones for candidates that progress to registration. The contract also includes additional potential commercial milestones of up to USD120m plus royalties on launched products.
Sichuan Kelun-Biotech presents positive Phase 3 trial results for sac-TMT
Clarity Pharmaceuticals signs copper-67 supply agreement with Nusano
SOPHiA DDM Digital Twins launched to simulate patient outcomes and support oncology decisions
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Jacobio Pharma partners with Oceanpine Capital to focus on core oncology pipeline
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress
Privo Technologies reports progress in oral cancer trial
Johnson & Johnson to separate its Orthopaedics business as standalone DePuy Synthes
Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
AstraZeneca strikes landmark drug pricing deal with US Government
Tempus selected by ARPA-H to provide CRO and testing services for ADAPT cancer programme